Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Mar 28:rs.3.rs-4103685.
doi: 10.21203/rs.3.rs-4103685/v1.

Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration

Rowan Saloner  1 Adam Staffaroni  1 Eric Dammer  2 Erik C B Johnson  3 Emily Paolillo  1 Amy Wise  1 Hilary Heuer  1 Leah Forsberg  4 Argentina Lario Lago  1 Julia Webb  1 Jacob Vogel  5 Alexander Santillo  5 Oskar Hansson  5 Joel Kramer  1 Bruce Miller  6 Jingyao Li  7 Joseph LoureiroRajeev Sivasankaran  8 Kathleen Worringer  9 Nicholas Seyfried  3 Jennifer Yokoyama  10 William Seeley  11 Salvatore Spina  1 Lea Grinberg  11 Lawren VandeVrede  1 Peter Ljubenkov  1 Ece Bayram  12 Andrea Bozoki  13 Danielle Brushaber  4 Ciaran Considine  14 Gregory Day  15 Bradford Dickerson  16 Kimiko Domoto-Reilly  17 Kelley Faber  18 Douglas Galasko  19 Daniel Geschwind  20 Nupur Ghoshal  21 Neill Graff-Radford  4 Chadwick Hales  2 Lawrence Honig  22 Ging-Yuek Hsiung  23 Edward Huey  22 John Kornak  1 Walter Kremers  4 Maria Lapid  4 Suzee Lee  1 Irene Litvan  24 Corey McMillan  25 Mario MendezToji Miyagawa  4 Alexander Pantelyat  26 Belen Pascual  27 Henry Paulson  28 Leonard Petrucelli  4 Peter Pressman  29 Eliana Ramos  30 Katya Rascovsky  1 Erik Roberson  31 Rodolfo Savica  4 Allison Snyder  32 A Campbell Sullivan  33 Carmela Tartaglia  34 Marijne Vandebergh  35 Bradley Boeve  4 Howie Rosen  1 Julio Rojas  1 Adam Boxer  36 Kaitlin Casaletto  1
Affiliations

Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration

Rowan Saloner et al. Res Sq. .

Update in

  • Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.
    Saloner R, Staffaroni AM, Dammer EB, Johnson ECB, Paolillo EW, Wise A, Heuer HW, Forsberg LK, Lario-Lago A, Webb JD, Vogel JW, Santillo AF, Hansson O, Kramer JH, Miller BL, Li J, Loureiro J, Sivasankaran R, Worringer KA, Seyfried NT, Yokoyama JS, Spina S, Grinberg LT, Seeley WW, VandeVrede L, Ljubenkov PA, Bayram E, Bozoki A, Brushaber D, Considine CM, Day GS, Dickerson BC, Domoto-Reilly K, Faber K, Galasko DR, Gendron T, Geschwind DH, Ghoshal N, Graff-Radford N, Hales CM, Honig LS, Hsiung GR, Huey ED, Kornak J, Kremers W, Lapid MI, Lee SE, Litvan I, McMillan CT, Mendez MF, Miyagawa T, Pantelyat A, Pascual B, Masdeu J, Paulson HL, Petrucelli L, Pressman P, Rademakers R, Ramos EM, Rascovsky K, Roberson ED, Savica R, Snyder A, Sullivan AC, Tartaglia MC, Vandebergh M, Boeve BF, Rosen HJ, Rojas JC, Boxer AL, Casaletto KB; ALLFTD Consortium. Saloner R, et al. Nat Aging. 2025 Jun;5(6):1143-1158. doi: 10.1038/s43587-025-00878-2. Epub 2025 May 16. Nat Aging. 2025. PMID: 40380000 Free PMC article.

Abstract

The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN, MAPT) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. 'Hub' proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

Competing Interests A.M.S. received research support from the NIA/NIH, the Bluefield Project to Cure FTD, and the Larry L. Hillblom Foundation. He has provided consultation to Alector, Lilly, Passage Bio, and Takeda. L.F. receives research support from the NIH. OH has received research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. J.S.Y. receives research support from the NIH. P.L. is a site primary investigator for clinical trials by Alector, AbbVie and Woolsey. He serves as an advisor for Retrotrope. He receives research and salary support from the NIH-NIA and the Alzheimer’s Association-Part the Cloud partnership. E.B. receives research support from the NIH and Lewy Body Dementia Association. B.C.D. is a consultant for Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Genentech, Lilly, Merck, Novartis, Takeda and Wave Lifesciences; receives royalties from Cambridge University Press, Elsevier and Oxford University Press; and receives grant funding from the NIA, the National Institute of Neurological Disorders and Stroke, the National Institute of Mental Health and the Bluefield Foundation. K.D.-R. receives research support from the NIH and serves as an investigator for a clinical trial sponsored by Lawson Health Research Institute. K.F. receives research support from the NIH. J.A.F. receives research support from the NIH. N.G. has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals, Janssen Immunotherapy, Novartis, Pfizer, Wyeth, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) and the A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) trial; and receives research support from Tau Consortium, the Association for Frontotemporal Dementia and the NIH. N.G.-R. receives royalties from UpToDate and has participated in multicenter therapy studies by sponsored by Biogen, TauRx, and Lilly; and receives research support from the NIH. C.M.H. is a Site PI or SubI for several industry (Alector, Janssen, Biogen, Cogito Tx) sponsored clinical trials with funding through Emory Office of Sponsored Programs. L.S.H. receives research funding from Abbvie, Acumen, Alector, Biogen, BMS, Eisai, Genentech/Roche, Janssen/J&J, Transposon, UCB, Vaccinex; and receives consulting fees from Biogen, Cortexyme, Eisai, Medscape, Prevail/Lilly. G.-Y.H. has served as an investigator for clinical trials sponsored by AstraZeneca, Eli Lilly and Roche/Genentech; and he receives research support from the Canadian Institutes of Health Research and the Alzheimer Society of British Columbia. E.D.H. receives research support from the NIH. J. Kornak has provided expert witness testimony for Teva Pharmaceuticals in Forest Laboratories Inc. et al. v. Teva Pharmaceuticals USA, Inc., case numbers 1:14-cv-00121 and 1:14-cv-00686 (D. Del. filed 31 January 2014 and 30 May 2014 regarding the drug Memantine) and for Apotex/HEC/Ezra in Novartis AG et al. v. Apotex Inc., case number 1:15-cv-975 (D. Del. filed 26 October 2015 regarding the drug Fingolimod); he has also given testimony on behalf of Puma Biotechnology in Hsingching Hsu et al, vs. Puma Biotechnology, Inc., et al. 2018 regarding the drug Neratinib; and he receives research support from the NIH. W.K. receives research funding from AstraZeneca, Biogen, Roche, the Department of Defense and the NIH. M.I.L. receives research support from the NIH. I.L.’s research is supported by the National Institutes of Health grants: 2R01AG038791–06A, U01NS100610, U01NS80818, R25NS098999; U19 AG063911–1 and 1R21NS114764–01A1; the Michael J Fox Foundation, Parkinson Foundation, Lewy Body Association, CurePSP, Roche, Abbvie, Biogen, Centogene. EIP-Pharma, Biohaven Pharmaceuticals, Novartis, Brain Neurotherapy Bio and United Biopharma SRL - UCB. She is a Scientific advisor for Amydis and Rossy Center for Progressive Supranuclear Palsy University of Toronto. She receives her salary from the University of California San Diego and as Chief Editor of Frontiers in Neurology. C.T.M receives funding from NIH and Penn Institute on Aging. M.F.M. receives research support from the NIH. A.P. receives research support from the NIH (U01 NS102035; K23 AG059891). H.P. receives research support from the NIH. L.P. receives research support from the NIH. E.M.R. receives research support from the NIH. K.R. receives research support from the NIH. E.D.R. has received research support from the NIH, the Bluefield Project to Cure Frontotemporal Dementia, the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation, the BrightFocus Foundation, and Alector; has served as a consultant for AGTC and on a data monitoring committee for Lilly; and owns intellectual property related to tau and progranulin. R.S. receives support from the NIA, the National Institute of Neurological Disorders and Stroke, the Parkinson’s Disease Foundation and Acadia Pharmaceuticals. M.C.T. has served as an investigator for clinical trials sponsored by Biogen, Avanex, Green Valley, Roche/Genentech, Bristol Myers Squibb, Eli Lilly/Avid Radiopharmaceuticals and Janssen. She receives research support from the Canadian Institutes of Health Research. B.F.B. has served as an investigator for clinical trials sponsored by Alector, Biogen, Transposon and Cognition Therapeutics. He serves on the Scientific Advisory Board of the Tau Consortium which is funded by the Rainwater Charitable Foundation. He receives research support from NIH. H.J.R. has received research support from Biogen Pharmaceuticals, has consulting agreements with Wave Neuroscience, Ionis Pharmaceuticals, Eisai Pharmaceuticals, and Genentech, and receives research support from the NIH and the state of California. J.C.R. receives research support from the NIH and is a site principal investigator for clinical trials sponsored by Eli Lilly and Eisai. A.L.B. receives research support from the NIH, the Tau Research Consortium, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Corticobasal Degeneration Solutions, the Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Association. He has served as a consultant for Aeovian, AGTC, Alector, Arkuda, Arvinas, Boehringer Ingelheim, Denali, GSK, Life Edit, Humana, Oligomerix, Oscotec, Roche, TrueBinding, Wave, Merck and received research support from Biogen, Eisai and Regeneron.

Figures

Figure 1
Figure 1. Study Overview.
Cerebrospinal fluid (CSF) was collected in 116 carriers of autosomal dominant mutations for frontotemporal lobar degeneration (FTLD; 47 C9orf72 [C9], 32 GRN, 37 MAPT) and 39 non-carrier controls with a family history of genetic FTLD. CSF was analyzed on a modified aptamer-based assay (SomaScan). After data processing, a total of 4,138 proteins were quantified. High-dimensional proteomic data were organized into modules of protein co-expression using weighted gene co-expression network analysis (WGCNA). CSF protein co-expression modules from the genetic FTLD network were functionally annotated using gene set and cell type enrichment approaches. CSF genetic FTLD modules were examined in relation to cross-sectional (CDR®+NACC-FTLD, CSF neurofilament light [NfL]) and longitudinal (global cognitive trajectories) indicators of disease severity. In cross-cohort and cross-platform validation analyses, genetic FTLD modules were reconstructed in independent cohorts of sporadic PSP-Richardson syndrome (PSP-RS) and controls (4RTNI; SomaScan) and FTLD, AD, and controls (BioFINDER 2; Olink).
Figure 2
Figure 2. Genetic FTLD Protein Co-Expression Network.
A) A cerebrospinal fluid (CSF) protein co-expression network was built using weighted gene correlational network analysis (WGCNA). The genetic FLTD network consisted of 31 protein co-expression modules. Module relatedness is shown in the dendrogram to the right. GO analysis was used to identify the principal biology represented by each module. Within genes, module eigenproteins in symptomatic (Sx) and presymptomatic (PreSx) variant carriers were compared against controls. Increased eigenprotein abundance in FTLD is indicated in green, whereas decreased eigenprotein abundance is indicated in blue. Module eigenproteins were correlated with disease outcomes, including CDR®+NACC-FTLD, global cognitive slope, and CSF NfL (red, positive correlation; blue, negative correlation). The cell type nature of each module was assessed by module protein overlap with cell-type-specific marker lists of neurons, oligodendrocytes, astrocytes, microglia and endothelia. Asterisks in the left heatmap indicate statistical significance after Tukey’s test. Asterisks in the middle and right heatmaps indicate statistical significance after false discovery rate correction. B) Module eigenprotein levels by case status for six of the most strongly FTLD-associated modules. Mutation carriers are grouped by Sx and PreSx individuals. C9: 24 PreSx, 23 Sx; GRN: 12 PreSx, 19 Sx; MAPT: 18 PreSx, 19 Sx. Differences in module eigenprotein by case status were assessed by one-way ANOVA with Tukey test. Gene-specific p-values represent the omnibus significance for gene-stratified comparisons vs. controls. Box plots represent the median and 25th and 75th percentiles, and box hinges represent the interquartile range of the two middle quartiles within a group. Min and max data points define the extent of whiskers (error bars). CTL, control.
Figure 3
Figure 3. Module and Hub Protein Relationships with Cognitive Trajectory.
Plots display the top 5 CSF genetic FTLD network modules most strongly associated with global cognitive trajectories in the full sample. Eigenprotein z-scores are plotted against the annual rate of global cognitive change during the study period (n = 137). Person-specific cognitive slopes were extracted from linear mixed-effects models that included baseline demographics (age, sex, education) and time (years since baseline). Confidence bands represent 95% confidence intervals for Spearman’s r values. Information on the association between all network module eigenproteins and cognitive trajectory in the full sample, within each gene, and within presymptomatic mutation carriers is provided in Supplementary Table 7. For proteins assigned to each module, an individual protein’s strength of connectivity to the module (x-axis) is plotted against the individual protein’s correlation with global cognitive change (y-axis). Proteins that exhibited stronger intramodular connectivity also exhibited stronger relationships with cognitive slope. Color-filled triangles represent individual proteins that survived false discovery rate (FDR) correction in proteome-wide differential correlational analyses (n=646 total proteins, full list in Supplementary Table 7). Proteins in the top 20th percentile of intramodular connectivity and are classified as ‘hub’ proteins. Hub proteins that significantly correlated with cognitive trajectory are listed with each plot.
Figure 4
Figure 4. Cross-Cohort Validation.
Validation cohorts included 4RTNI, composed of PSP and controls, and BioFINDER 2, composed of patients with frontotemporal dementia clinical syndromes, biomarker-confirmed Alzheimer’s disease (AD), and controls. 4RTNI CSF samples were assayed with SomaScan and BioFINDER CSF samples were assayed with Olink. A) Weighted gene correlational network analysis was applied to 4RTNI SomaScan data to test for module preservation across the genetic FTLD and sporadic PSP-Richardson syndrome (PSP-RS) networks. Modules that have a Zsummary score greater than or equal to 1.96 (or q = 0.05, blue dotted line) are considered to be preserved, and modules that have a Zsummary score greater than or equal to 10 (or q = 1 × 10−23, red dotted line) are considered to be highly preserved. All modules in the genetic FTLD network were highly preserved in the sporadic PSP-RS network. B) Synthetic eigenproteins were reconstructed in 4RTNI and BioFINDER 2 to test for concordance in module relationships with disease groups. Heatmap displays average synthentic eigenprotein z-score differences between PSP-RS and controls (CTL), FTLD vs. CTL, FTLD vs. AD, and AD vs. CTL. Asterisks indicate statistical significance after false discovery rate correction C, D) Synthetic eigenprotein boxplots for key modules from 4RTNI (C) and BioFINDER 2 (D) analyses. Pairwise differences in module synthetic eigenproteins by case status were assessed by two-sided t-test with FDR-correction. Box plots represent the median and 25th and 75th percentiles, and box hinges represent the interquartile range of the two middle quartiles within a group. Min and max data points define the extent of whiskers (error bars).
Figure 5
Figure 5. Genetic FTLD CSF Network Module Over-Representation Analysis with AD CSF Networks.
Module member overrepresentation analysis (ORA) of the genetic FTLD CSF network with two CSF protein co-expression networks in Alzheimer’s disease (AD): 1) 3-platform network, obtained using SomaScan, Olink, and tandem mass tag-based mass spectrometry (TMT-MS; Dammer et al.); 2) single platform network obtained using TMT-MS (Modeste et al.). Box values represent −log10(FDR) value for pairwise module overlap, determined using one-tailed Fisher’s exact test. Bolded AD network modules significantly differed between AD and controls. Modules from the AD networks (y-axis rows) without an overlap value of − log10(FDR) > 1 are not included in the heatmaps.

Similar articles

Cited by

  • Opposing role of phagocytic receptors MERTK and AXL in Progranulin deficient FTD.
    Clelland CD, Fan L, Saloner R, Etchegaray JI, Altobelli CR, Salomonsson S, Maltos AM, Sachdev A, Zhu J, Lee SI, Li Y, Zhou Y, Le D, Wang C, Carling G, Kodama L, Sayed F, Perez-Bermejo JA, Geier EG, Yokoyama JS, Rosen H, Nana AL, Spina S, Grinberg LT, Seeley WW, Elahi F, Boxer AL, Arkin MR, Gan L. Clelland CD, et al. Commun Biol. 2025 Jul 1;8(1):971. doi: 10.1038/s42003-025-08368-2. Commun Biol. 2025. PMID: 40596721 Free PMC article.

References

    1. Bang J, Spina S, Miller BL (2015) Frontotemporal dementia. Lancet 386:1672–1682 - PMC - PubMed
    1. Knopman DS, Roberts RO (2011) Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci 45:330–335 - PMC - PubMed
    1. Mackenzie IRA, Neumann M (2016) Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem 138:54–70 - PubMed
    1. Rojas JC et al. (2021) Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology 96:e2296–e2312 - PMC - PubMed
    1. Rosen HJ, Boeve BF, Boxer AL (2020) Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. Alzheimers Dement 16:71–78 - PMC - PubMed

Publication types

LinkOut - more resources